Nature Cancer, Published online: 14 September 2026; doi:10.1038/s43018-026-01235-x

We identified a metabolic signaling axis that enables pancreatic cancer cells to survive chemotherapy by suppressing ferroptosis. Targeting of the valine catabolism enzyme MMSDH reverses this chemoresistance and shows promise as a potential component of combination strategies against refractory tumors.

Nature Cancer, Published online: 14 September 2026; doi:10.1038/s43018-026-01237-9

Marsoni et al. evaluated the feasibility of a dynamic circulating tumor DNA-guided adjuvant and postadjuvant treatment strategy in patients with resected microsatellite-stable, high-risk stage II or III colon cancer in the phase 2 PEGASUS trial.

Nature Cancer, Published online: 11 September 2026; doi:10.1038/s43018-026-01236-w

Zheng et al. describe how hypoxia-induced methylmalonate semialdehyde dehydrogenase lactylation promotes acyl-CoA synthetase long-chain family member 4 propionylation and degradation, thereby suppressing ferroptosis induced by chemotherapy, and develop a blocking peptide that increased chemotherapy efficacy in pancreatic ductal adenocarcinoma.

Nature Cancer, Published online: 09 September 2026; doi:10.1038/s43018-026-01229-9

Lai et al. show that Nakaseomyces glabratus is enriched in fecal and tumor samples of patients with castration-resistant prostate cancer and that administration of the fungus accelerates cancer progression in prostate cancer-bearing castrated mice.

Nature Cancer, Published online: 01 September 2026; doi:10.1038/s43018-026-01231-1

The addition of oral l-glutamine to first-line gemcitabine plus nab-paclitaxel appears safe and is associated with improved survival outcomes and tumor responses compared with historical benchmarks in untreated advanced pancreatic cancer. The beneficial effects of l-glutamine may be mediated through modulation of intermediary metabolism, gut microbial function, inflammatory responses and gut barrier integrity.

Nature Cancer, Published online: 01 September 2026; doi:10.1038/s43018-026-01243-x

Publisher Correction: Adjuvant personalized multivalent neoantigen DNA vaccination for MGMT unmethylated glioblastoma: a phase 1 trial

Nature Cancer, Published online: 01 September 2026; doi:10.1038/s43018-026-01220-4

Chen et al. have developed SlideChat, a multimodal generative artificial intelligence assistant, which they benchmark on 27 pathology tasks across 33 cancer types. Expert pathologists rated the assistant as clinically relevant and accurate.

Nature Cancer, Published online: 31 August 2026; doi:10.1038/s43018-026-01225-z

In this open-label, single-arm, phase 1 GlutaPanc trial, Gong and colleagues report the safety and feasibility of l-glutamine in participants with advanced pancreatic ductal adenocarcinoma and determine the recommended phase 2 dose of l-glutamine in combination with gemcitabine and nab-paclitaxel.

Nature Cancer, Published online: 25 August 2026; doi:10.1038/s43018-026-01241-z

Author Correction: Low-protein diet enhances antitumor immunity in pancreatic cancer through microbiota-derived UDP-galactose

Nature Cancer, Published online: 25 August 2026; doi:10.1038/s43018-026-01221-3

Chen and colleagues report that the neuropeptide galanin impairs antitumor immunity in glioblastoma by interacting with its receptor GALR3 on monocytic myeloid-derived suppressor cells, promoting their infiltration and ferroptosis resistance.

Nature Cancer, Published online: 21 August 2026; doi:10.1038/s43018-026-01219-x

Paul Mischel obtained his MD from Cornell University Medical College, trained in anatomic and neuropathology at UCLA and did post-doctoral research training in Louis Reichardt’s lab at HHMI/UCSF. He is the Fortinet Founders Professor, vice chair for research for the department of pathology, and deputy director of translational science and an institute scholar at Sarafan ChEM-H, Stanford University. Mischel leads Team eDyNAmiC of the Cancer Grand Challenges Program. He is a member of the National Academy of Medicine, a fellow of the AACR Academy, and past president of the American Society for Clinical Investigation.

Nature Cancer, Published online: 25 May 2026; doi:10.1038/s43018-026-01177-4

Wong et al. uncover a nutritional dependency for acute lymphoblastic leukemia cells that spread to the central nervous system and propose using copper restriction to impair leukemia progression by disrupting nucleotide synthesis through the inhibition of electron transport chain activity.

Nature Cancer, Published online: 25 May 2026; doi:10.1038/s43018-026-01165-8

In this phase 2 trial, Perez et al. reported the safety of the vitamin D receptor agonist paricalcitol with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma and the pharmacodynamic effects of paricalcitol in fibroblasts and immune cells.

Nature Cancer, Published online: 22 May 2026; doi:10.1038/s43018-026-01167-6

Ahmed and colleagues show that, by promoting ‘dressing’ of intact tumor target antigens onto dendritic cells, tumor irradiation enhances chimeric antigen receptor T cell persistence and efficacy in lung metastasis models.

Nature Cancer, Published online: 20 May 2026; doi:10.1038/s43018-026-01168-5

Castro-Dopico et al. report the design of reagents to bridge F-actin and Fcγ receptors, endowing a range of antigen-presenting cells with the ability to cross-present antigens from dead tumor cells and boosting antitumor immunity in preclinical models.

Nature Cancer, Published online: 19 May 2026; doi:10.1038/s43018-026-01174-7

Tang et al. identify cysteinyl leukotriene receptor 1 (CysLTR1) as a critical regulator of tumor-induced myelopoiesis, suggesting CysLTR1 targeting to sensitize tumors to immune checkpoint blockade.

Nature Cancer, Published online: 18 May 2026; doi:10.1038/s43018-026-01162-x

We report the results of a phase 1 clinical trial (NCT04015700) evaluating the safety and immunogenicity of GNOS-PV01, a personalized DNA cancer vaccine, in patients with MGMT-unmethylated glioblastoma, after surgery and radiotherapy. Immune responses were detected in all but one patient, who received immunosuppressive steroids. The 24-month overall survival was 33%, including one patient who was alive more than 48 months after diagnosis.

Nature Cancer, Published online: 15 May 2026; doi:10.1038/s43018-026-01169-4

Zhao and colleagues show that CD300ld, upregulated in pathologically activated neutrophils, mediates contact-dependent suppression of cytotoxic CD8+ T cells by binding to phosphatidylserine, inhibiting antitumor immune responses.

Nature Cancer, Published online: 15 May 2026; doi:10.1038/s43018-026-01172-9

Jayaram et al. assessed the performance of the combination of circulating tumor DNA and serum prostate-specific antigen for dynamic monitoring of metastatic prostate cancer at first-line treatment in this prospective observational clinical trial.

Nature Cancer, Published online: 03 April 2026; doi:10.1038/s43018-025-01108-9

Applications of digital pathology in clinical oncology have largely depended on the requirement for labeled data and model re-training. A study now presents PRET, a training-free framework with robust performance for pan-cancer diagnosis that adapts pathology foundation models to diverse tasks at inference stage, from screening and subtyping tasks to segmentation and metastasis detection tasks.